Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects

被引:36
|
作者
Al-Hamodi, Zaid [1 ]
Ismail, Ikram S. [2 ]
Saif-Ali, Riyadh [1 ,3 ]
Ahmed, Khaled A. [4 ]
Muniandy, Sekaran [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Med Ctr, Dept Med, Kuala Lumpur 50603, Malaysia
[3] Sanaa Univ, Fac Med, Dept Biochem, Sanaa, Yemen
[4] Ibb Univ, Fac Dent, Ibb, Yemen
来源
关键词
CORONARY-HEART-DISEASE; INSULIN-RESISTANCE SYNDROME; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; RISK-FACTORS; FIBRINOLYTIC SYSTEM; PREDICTIVE-VALUE; PLASMA; OBESITY; INFLAMMATION;
D O I
10.1186/1475-2840-10-23
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of developing cardiovascular diseases (CVD) and fibrinolytic abnormalities. The aim of this study was to investigate the association of tPA and its inhibitor PAI-1 with type 2 diabetes (T2D) and MetS and interrelationship between PAI-1 and tPA activities and antigens in Malaysian T2D and normal subjects. Methods: The plasma activities and antigens of PAI-1 and tPA and the levels of the tPA/PAI-1 complex as well as serum insulin, parameter of the coronary risk panel and plasma glucose at fasting state were studied in 303 T2D subjects (227 with MetS and 76 without MetS), 131 normal non-diabetic non-metabolic subjects and 101 nondiabetic MetS subjects. Results: The PAI-1 activity was higher in subjects with T2D with MetS (P = 9.8 x 10(-19)) and non-diabetic subjects with MetS (P = 3.0 x 10(-15)), whereas the tPA activity was lower in T2D with MetS (P = 0.003) as compare to normal subjects. Plasma tPA antigen levels were higher in subjects with T2D with MetS (P = 8.9 x 10(-24)), T2D without MetS (P = 1.3 x 10(-13)) and non-diabetic MetS subjects (P = 0.002). The activity and antigen of PAI-1 in normal subjects were related to insulin resistance (P = 2.2 x 10(-4); 0.007). Additionally, the PAI-1 activity was associated with an increased waist circumference (P = 2.2 x 10(-4)) and decreased HDL-c (P = 0.005), whereas the tPA activity was associated with decreased FBG (P = 0.028). The highest correlation was between PAI-1 activity and its antigen (R-2 = 0.695, P = 1.1 x 10(-36)) in diabetic subjects. The tPA activity negatively correlated with its antigen (R-2 = -0.444, P = 7.7 x 10(-13)) in normal subjects and with the PAI-1 activity and antigen (R-2 = -0.319, P = 9.9 x 10(-12); R2 = -0.228, P = 3.4 x 10(-6)) in diabetic subjects. Conclusions: PAI-1 and tPA activities and antigens were associated with diabetes and MetS parameters in Malaysian subjects.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] There is no covalent interaction between plasminogen activator inhibitor-1 with urokinase-type plasminogen activator
    Wang, Q
    Shaltiel, S
    MOLECULAR BIOLOGY OF THE CELL, 2002, 13 : 513A - 513A
  • [32] Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1
    Lin, Zhonghui
    Jiang, Longguang
    Yuan, Cai
    Jensen, Jan K.
    Zhang, Xu
    Luo, Zhipu
    Furie, Barbara C.
    Furie, Bruce
    Andreasen, Peter A.
    Huang, Mingdong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (09) : 7027 - 7032
  • [33] Protection by alpha 2-macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor-1
    Ieko, M
    Sawada, K
    Yasukouchi, T
    Sakurama, S
    Tohma, Y
    Shiroshita, K
    Kurosawa, S
    Ohmoto, A
    Kohno, M
    Satoh, M
    Koike, T
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (01) : 214 - 218
  • [34] Expression of urokinase type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer
    Kawasaki, K
    Hayashi, Y
    Wang, Y
    Suzuki, S
    Morita, Y
    Nakamura, T
    Narita, K
    Doe, W
    Itoh, H
    Kuroda, Y
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (09) : 936 - 944
  • [35] Effect of carbohydrate side chain of tissue-type plasminogen activator on its interaction with plasminogen activator inhibitor-1
    Madoiwa, S
    Arai, K
    Mimuro, J
    Mori, K
    Asakura, S
    Matsuda, M
    Sakata, Y
    FIBRINOLYSIS & PROTEOLYSIS, 1998, 12 (01): : 17 - 22
  • [36] VITRONECTIN GOVERNS THE INTERACTION BETWEEN PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    KEIJER, J
    EHRLICH, HJ
    LINDERS, M
    PREISSNER, KT
    PANNEKOEK, H
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (16) : 10700 - 10707
  • [37] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and-2 in hepatocellular carcinoma
    Zhou, L
    Hayashi, Y
    Itoh, T
    Wang, WP
    Rui, JA
    Itoh, H
    PATHOLOGY INTERNATIONAL, 2000, 50 (05) : 392 - 397
  • [38] Plasminogen activator/plasminogen activator inhibitor-1 and cytokine modulation by the PROACT™ system
    Ivarsson, ML
    Diamond, MP
    Falk, P
    Holmdahl, L
    FERTILITY AND STERILITY, 2003, 79 (04) : 987 - 992
  • [39] Plasminogen activator inhibitor-1 and tissue plasminogen activator and incident AF: Data from the PREVEND study
    Mulder, Bart A.
    Geelhoed, Bastiaan
    van der Harst, Pim
    Spronk, Henri M.
    Van Gelder, Isabelle C.
    Asselbergs, Folkert W.
    Rienstra, Michiel
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 272 : 208 - 210
  • [40] Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
    Zuo, Yu
    Warnock, Mark
    Harbaugh, Alyssa
    Yalavarthi, Srilakshmi
    Gockman, Kelsey
    Zuo, Melanie
    Madison, Jacqueline A.
    Knight, Jason S.
    Kanthi, Yogendra
    Lawrence, Daniel A.
    SCIENTIFIC REPORTS, 2021, 11 (01)